Workflow
Immunocore(IMCR)
icon
Search documents
Immunocore(IMCR) - 2025 Q2 - Earnings Call Transcript
2025-08-07 13:00
Immunocore Holdings (IMCR) Q2 2025 Earnings Call August 07, 2025 08:00 AM ET Speaker0Greetings, and welcome to the ImmunoCor conference call and webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation, and you may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Clayton Robertson, Investor Relation ...
Immunocore(IMCR) - 2025 Q2 - Earnings Call Presentation
2025-08-07 12:00
Transformative immunomodulating medicines for patients 2Q & 1H 2025 Financial Results & Business Update 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate", "continue" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to ...
Immunocore(IMCR) - 2025 Q2 - Quarterly Results
2025-08-07 11:40
Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Exhibit 99.1 Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H ...
Immunocore(IMCR) - 2025 Q2 - Quarterly Report
2025-08-07 11:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not Ap ...
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
Globenewswire· 2025-07-31 06:00
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025. Following the announ ...
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
ZACKS· 2025-07-24 14:56
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $36.05, gaining 12.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $62.13 indicates a 72.3% upside potential.The average comprises 15 short-term price targets ranging from a low of $24.00 to a high of $100.00, with a standard deviation of $22.46. While the lowest estimate indicates a decline of 33.4% ...
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
ZACKS· 2025-07-02 14:30
Industry Overview - The biotech industry has shown resilience amid global trade tensions, with ongoing geopolitical issues presenting challenges, yet the demand for innovative medical treatments remains strong [1] - Strategic collaborations and acquisitions are increasingly common as large pharma and biotech companies seek to expand their product portfolios and pipelines, particularly in the context of AI-driven drug discovery [2][9] - The Zacks Biomedical and Genetics industry is currently ranked 86, placing it in the top 35% of over 246 Zacks industries, indicating a decent outlook driven by consistent demand for medical advancements [15] Market Trends - The focus on high-profile drug performance and innovative pipeline development is critical, with significant R&D expenditures required to create breakthrough treatments [6] - Successful commercialization is essential for drug uptake, often leading smaller biotech firms to collaborate with larger companies for shared sales or royalties [7] - The recent emphasis on AI technology for drug discovery is expected to attract further investment into the biotech sector [11] Company Performance - Exelixis, Inc. (EXEL) is positioned well with its lead drug, Cabometyx, which is gaining traction in the oncology market, and its shares have surged 31% year to date [35][36] - Verona Pharma (VRNA) has seen a 94.8% increase in shares year to date, driven by the uptake of its drug Ohtuvayre for COPD, with further growth anticipated [24] - Alkermes (ALKS) is benefiting from strong sales of its proprietary drugs and has a Zacks Rank of 1, with EPS estimates for 2025 rising to $1.79 [26][27] - Immunocore Holdings (IMCR) focuses on TCR bispecific immunotherapies and has gained 11.4% year to date, with ongoing studies expected to enhance its market position [30][32] - Kiniska Pharmaceuticals (KNSA) is experiencing growth with its FDA-approved drug Arcalyst and has seen a 37.7% increase in shares [39][40]
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
GlobeNewswire News Room· 2025-06-30 12:00
Core Insights - Er-Kim has been appointed by Immunocore as the distribution and commercialization partner for KIMMTRAK in Turkey and the MENA, Caucasus, and CIS regions [1][3] - KIMMTRAK is a treatment for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma [1][2][4] - The partnership aims to improve access to innovative cancer treatments in regions with high unmet medical needs [3] Company Overview - Er-Kim, established in 1981, specializes in biopharmaceutical innovation and has partnered with over 40 global leaders [3] - The company has a reach of over 600 million patients and generates revenues exceeding EUR 305 million [3] - Er-Kim employs over 300 professionals worldwide and focuses on sustainable and flexible business models [3] Product Information - KIMMTRAK (tebentafusp) is approved in certain countries as a monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [4] - The availability and prescribing conditions for KIMMTRAK may vary by country [4]
Immunocore Holdings (IMCR) Earnings Call Presentation
2025-06-23 11:48
Transformative immunomodulating medicines for patients May 2025 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements ...
Immunocore Holdings (IMCR) 2025 Conference Transcript
2025-06-05 16:05
Summary of Immunocore Holdings (IMCR) 2025 Conference Call Company Overview - **Company**: Immunocore Holdings (IMCR) - **Focus**: Development and commercialization of innovative therapies for cancer and infectious diseases, particularly in uveal melanoma and cutaneous melanoma Key Points Financial Performance - **ChemTrak Revenue**: Achieved net revenues of $94 million in Q1, representing a 33% year-over-year increase, marking the twelfth consecutive quarter of growth [6][7] - **One-time Revenue Adjustment**: Recognized a one-time revenue adjustment of $6 million due to finalized pricing agreements in France and Germany [7] Product Pipeline and Growth Strategy - **ChemTrak**: - Expected to exceed $300 million in revenue [2] - Focus on increasing penetration in the U.S. market, currently at 65% for HLA-O2-01 positive metastatic uveal melanoma patients [9] - Plans for new launches in 26 countries, with recent launches in the UK, Poland, and the Netherlands [14] - Duration of therapy is around 12 months, which is an improvement from the clinical trial data of 10 months [16][18] - **Competition**: - Acknowledgment of potential competition from another company, Idea, which is developing an oral therapy for melanoma [29] - Emphasis on ChemTrak being the first approved medicine for HLA-2-01 patients in over 40 years, with a median overall survival of 22 months [32][34] Clinical Trials - **Cutaneous Melanoma Trials**: - Ongoing pivotal Phase 2/3 trial for ChemTrak in combination with pembrolizumab, targeting overall survival as the primary endpoint [43] - Historical one-year survival rate in late-line cutaneous melanoma was 75%, compared to 55% historically [44] - **PRAME Study**: - Phase 3 randomized controlled study of PRAME plus PD-1 in first-line melanoma, with a focus on progression-free survival (PFS) as the primary endpoint [68][90] - Confidence in the study's design based on previous data showing disease stabilization and T-cell fitness improvement [73][81] New Developments - **PWIL Target**: - New TCR bispecific targeting PWIL, expressed in colorectal cancer, gastric, and pancreatic cancers, currently in dose escalation [115] - **HIV Program**: - Ongoing dose escalation studies with promising initial data indicating biological activity [124][126] Additional Insights - **Market Position**: ChemTrak is positioned as the standard of care and the most prescribed medicine across major markets, making it challenging for competitors to displace it [40] - **Long-term Survival Data**: The company has established long-term survival data, with 27% of patients alive at three years, which is unprecedented in this field [36][38] - **Focus on Early Detection**: Efforts are being made to find patients earlier to improve outcomes and duration of therapy [15][24] This summary encapsulates the key discussions and insights from the Immunocore Holdings conference call, highlighting the company's financial performance, product pipeline, clinical trials, and competitive landscape.